- Email: [email protected]
5354554 Crosslinked antibodies and processes for their preparation
P A T E N T ABSTRACTS express the NPRB, DNA encoding NPRB and diagnostic and therapeutic uses for the NPRB and the DNA encoding NPRB.
5352589 DELETION MUTANT OF BASIC FIBROBLAST GROWTH FACTOR AND PRODUCTION THEREOF Laur Bergonzoni, Antoneila Isacchi, Paolo Sarmientos, Gilles Cauet, Milan, Italy assigned to Farmitalia Carlo Erba S R L The present invention relates to the production, by recombinant DNA techniques, of derivatives of basic fibroblast growth factor CoFGF). These derivatives of bFGF can act as antagonists and/ or superasonists of the wild type molecule in the angingenic process. These derivatives, as well as wild type bFGF, may be prepared by the use of strains or E. coli which have been transformed with plasmids carrying nuclcotide seqluence coding for human and bovine bFGF and their derivatives.
5352769 ENZYMATIC REMOVAL OF A PROTEIN AMINO-TERMINAL SEQUENCE
305
interleukin-2 has been discovered. This protein has a molecular weight of about 75,000 (Mr) and is further characterized as having an affinity for IL-2 (in the absence of other receptor proteins) of about 109 molar and is substantially unreactive with anti-Tac antibodies. This new cellular protein, referred to herein as the alpha chain, is believed to interact with the previously isolated 55,000 dalton receptor protein (referred to herein as the beta chain ) to form the high alTmity interlenkin-2 receptor which triggers the growth and mitosis of T cells during an immune response. Methods for isolating and purifying the alpha chain protein are disclosed here~ as well as techniques for cloning and expressing the protein and related materials. Techniques for raising monoclonal antibodies to such proteins are also disclosed. Diagnostic and therapeutic uses for the novel receptor protein (or parlicular epitopes thereof) as well as monoclonal antibodies (or active fragments) reactive therewith are proposed. 5352783 MICROBIAL TRANSFORMATION PRODUCT HAVING IMMUNOSUPPRESSIVE ACTIVITY All Shafiee, Byron Arison, Shieh-Shung T Chen, Randall Miller, Ralph Stearns assigned to Merck & Co Inc
Gerald W Becker, Thomas C Furman, Warren
C MucKellar, James P McDonough assigned to Eli Lilly and Company
This disclosure relates to new compounds and to a process for the controlled conversion of such compounds to produce a Protein that comprises an amino acid sequence which is useful as a precursor to human insulin or to a modified human insulin, the amino ~ u s portion of which sequence does not define a cathepein C dipeptide removal stop point. The compounds have the formula Met-Y-Protein in which Y is Tyr or Arg.
5352772 75 KILODALTON INTERLEUKIN-2 RECEPTOR PROTEINS AND THEIR USES Kendall Smith assigned to The Trustees of Dartmouth College; United States of Ameri A new cellular protein produced by activated T cells and involved in the high affinity binding of
Microbial transformation of a macrolide immunosuppressant by the microorganism St=eptomyces sp., (Merck Culture Collection MA 6960) ATCC No. 55387 yields a compound of the structural formula (I): See Patent for Chemical Structure I See Patent for Tabular Presentation This compound is an immunosuppressant useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
5354554 CROSSLINKED ANTIBODIES AND PROCESSES FOR THEIR PREPARATION Stephen K Rhind, Wooburn, United Kingdom assigned to Celltech Limited Cross-linked labelled antibody conjugates are described which have at least one non-disulphide interchain bridge. The bridge may be the
306
PATENT ABSTRACTS
residue of a homo-or heterofunctional crosslinking reagent, and is located away from the antigen binding domain.~ of the antibody. The antibody conjugates have an enhanced binding capacity and in vivo have good blood clearance and, in the presence of a tnmour high tumour: blood and tumour: bone ratios. The conjugates are of use in the diagnosis and therapy of c.g. tnmours and may be prepared by reaction of a cross-linking reagent with an antibody.
5354661 MONOCLONAL ANTIBODY TO ENTEROHEMORRHAGIC ESCHERICHIA COLI 0157:H7 AND 026:Hll AND METHOD FOR DETECTION Michael P Doyle, Nish Padhye assigned to Wisconsin Alumni Research Foundation PCT No. PCT/US91/05310 Sec. 371 Date May 26, 1992 Sec. 102(e) Date May 26, 1992 PCT Filed Jul. 26, 1991.A monoclonal antibody specific for enterohemorrhagic Escherichia coil 0157:H7 and 026:H11 is produced by immunizing BALB/c mice with a strain of E. coil 0157:H7. The antibody reacts strongly by an enzyme-linked immunosorbent assay with an approximately 5,000-6,000 dalton molecular weight outer membrane protein of strains of enterohemorrhagic Escherichia coil 0157:H7 and 026:Hll. A rapid and sensitive assay for detecting these organisms is also disclosed.
5356622 FLEA
MIDGUT-SUPERNATANT VACCINES
Andrew W Heath, Miles Yamanaka, Ann Arfsten, Beverly Dale assigned to Paravax Inc A vaccine for protecting avian and mammalian subjects against flea infestation comprises the supernatant fraction of flea midgnt, or the antigenic components thereof. This also has the effect of reducing flea populations in the environment of the subject. Antibodies raised by these vaccines are also useful in purification and diagnosis. 5356797 MEMBRANE EXPRESSION OF HETEROLOGOUS GENES David W Niesel, J Scott Moncrief, Linda H Phillips assigned to Board of Regents The University of Texas The invention relates to nucleic acid segments useful in the construction of expression vectors for expression of heterologons polypeptides directed to particular areas of the host cell. Selected constructs direct production of polypeptides to the outer membrane surface of the cell. Other constructs direct expression of heterologons polypeptides to the inner membraue/periplasm of the host cell. Transformed host cells are potentially useful for the production of vaccines or immtmogens elicited in response to antigens expressed on the outer membranes of the host cells.
5354665
5356798 RECOMBINANT DNA PROCESSES FOR PRODUCING PI-LINKED LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN-3 Barbara Wallner, Catherin Hession assigned to Biogen Inc A phosphatidylinositol (PI)-linked form of the LFA-3 polypeptide, which binds to CD2 molecules on the surface of T lymphocytes, in provided. Soluble polypeptides derived from the native sequence are also disclosed. D N A sequences, vectors, and transformed unicellular hosts useful for making these polypeptides are provided. Methods for using the LFA-3 polypeptides in therapy an diagnosis are described.
RECOMBINANT PROTEIN P R O D U C T I O N IN SERUM-FREE MEDIUM Lei Kongerslev, John Pedersen, Birkerod, Denmark assigned to Novo Nordisk A/S In a method for effecting an increased expression in serum-free medium of recombinant proteins in a host cell being able to express said protein said host is cultured in a serum-free medium comprising an egg yolk fraction being free of fipoprotein and fipids so as to express said protein. Also the use of an egg yolk fraction being free of lipoprotein and fipids for increasing the expression of recombinant proteins in a host cell being able to express said
5352589 DELETION MUTANT OF BASIC FIBROBLAST GROWTH FACTOR AND PRODUCTION THEREOF Laur Bergonzoni, Antoneila Isacchi, Paolo Sarmientos, Gilles Cauet, Milan, Italy assigned to Farmitalia Carlo Erba S R L The present invention relates to the production, by recombinant DNA techniques, of derivatives of basic fibroblast growth factor CoFGF). These derivatives of bFGF can act as antagonists and/ or superasonists of the wild type molecule in the angingenic process. These derivatives, as well as wild type bFGF, may be prepared by the use of strains or E. coli which have been transformed with plasmids carrying nuclcotide seqluence coding for human and bovine bFGF and their derivatives.
5352769 ENZYMATIC REMOVAL OF A PROTEIN AMINO-TERMINAL SEQUENCE
305
interleukin-2 has been discovered. This protein has a molecular weight of about 75,000 (Mr) and is further characterized as having an affinity for IL-2 (in the absence of other receptor proteins) of about 109 molar and is substantially unreactive with anti-Tac antibodies. This new cellular protein, referred to herein as the alpha chain, is believed to interact with the previously isolated 55,000 dalton receptor protein (referred to herein as the beta chain ) to form the high alTmity interlenkin-2 receptor which triggers the growth and mitosis of T cells during an immune response. Methods for isolating and purifying the alpha chain protein are disclosed here~ as well as techniques for cloning and expressing the protein and related materials. Techniques for raising monoclonal antibodies to such proteins are also disclosed. Diagnostic and therapeutic uses for the novel receptor protein (or parlicular epitopes thereof) as well as monoclonal antibodies (or active fragments) reactive therewith are proposed. 5352783 MICROBIAL TRANSFORMATION PRODUCT HAVING IMMUNOSUPPRESSIVE ACTIVITY All Shafiee, Byron Arison, Shieh-Shung T Chen, Randall Miller, Ralph Stearns assigned to Merck & Co Inc
Gerald W Becker, Thomas C Furman, Warren
C MucKellar, James P McDonough assigned to Eli Lilly and Company
This disclosure relates to new compounds and to a process for the controlled conversion of such compounds to produce a Protein that comprises an amino acid sequence which is useful as a precursor to human insulin or to a modified human insulin, the amino ~ u s portion of which sequence does not define a cathepein C dipeptide removal stop point. The compounds have the formula Met-Y-Protein in which Y is Tyr or Arg.
5352772 75 KILODALTON INTERLEUKIN-2 RECEPTOR PROTEINS AND THEIR USES Kendall Smith assigned to The Trustees of Dartmouth College; United States of Ameri A new cellular protein produced by activated T cells and involved in the high affinity binding of
Microbial transformation of a macrolide immunosuppressant by the microorganism St=eptomyces sp., (Merck Culture Collection MA 6960) ATCC No. 55387 yields a compound of the structural formula (I): See Patent for Chemical Structure I See Patent for Tabular Presentation This compound is an immunosuppressant useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
5354554 CROSSLINKED ANTIBODIES AND PROCESSES FOR THEIR PREPARATION Stephen K Rhind, Wooburn, United Kingdom assigned to Celltech Limited Cross-linked labelled antibody conjugates are described which have at least one non-disulphide interchain bridge. The bridge may be the
306
PATENT ABSTRACTS
residue of a homo-or heterofunctional crosslinking reagent, and is located away from the antigen binding domain.~ of the antibody. The antibody conjugates have an enhanced binding capacity and in vivo have good blood clearance and, in the presence of a tnmour high tumour: blood and tumour: bone ratios. The conjugates are of use in the diagnosis and therapy of c.g. tnmours and may be prepared by reaction of a cross-linking reagent with an antibody.
5354661 MONOCLONAL ANTIBODY TO ENTEROHEMORRHAGIC ESCHERICHIA COLI 0157:H7 AND 026:Hll AND METHOD FOR DETECTION Michael P Doyle, Nish Padhye assigned to Wisconsin Alumni Research Foundation PCT No. PCT/US91/05310 Sec. 371 Date May 26, 1992 Sec. 102(e) Date May 26, 1992 PCT Filed Jul. 26, 1991.A monoclonal antibody specific for enterohemorrhagic Escherichia coil 0157:H7 and 026:H11 is produced by immunizing BALB/c mice with a strain of E. coil 0157:H7. The antibody reacts strongly by an enzyme-linked immunosorbent assay with an approximately 5,000-6,000 dalton molecular weight outer membrane protein of strains of enterohemorrhagic Escherichia coil 0157:H7 and 026:Hll. A rapid and sensitive assay for detecting these organisms is also disclosed.
5356622 FLEA
MIDGUT-SUPERNATANT VACCINES
Andrew W Heath, Miles Yamanaka, Ann Arfsten, Beverly Dale assigned to Paravax Inc A vaccine for protecting avian and mammalian subjects against flea infestation comprises the supernatant fraction of flea midgnt, or the antigenic components thereof. This also has the effect of reducing flea populations in the environment of the subject. Antibodies raised by these vaccines are also useful in purification and diagnosis. 5356797 MEMBRANE EXPRESSION OF HETEROLOGOUS GENES David W Niesel, J Scott Moncrief, Linda H Phillips assigned to Board of Regents The University of Texas The invention relates to nucleic acid segments useful in the construction of expression vectors for expression of heterologons polypeptides directed to particular areas of the host cell. Selected constructs direct production of polypeptides to the outer membrane surface of the cell. Other constructs direct expression of heterologons polypeptides to the inner membraue/periplasm of the host cell. Transformed host cells are potentially useful for the production of vaccines or immtmogens elicited in response to antigens expressed on the outer membranes of the host cells.
5354665
5356798 RECOMBINANT DNA PROCESSES FOR PRODUCING PI-LINKED LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN-3 Barbara Wallner, Catherin Hession assigned to Biogen Inc A phosphatidylinositol (PI)-linked form of the LFA-3 polypeptide, which binds to CD2 molecules on the surface of T lymphocytes, in provided. Soluble polypeptides derived from the native sequence are also disclosed. D N A sequences, vectors, and transformed unicellular hosts useful for making these polypeptides are provided. Methods for using the LFA-3 polypeptides in therapy an diagnosis are described.
RECOMBINANT PROTEIN P R O D U C T I O N IN SERUM-FREE MEDIUM Lei Kongerslev, John Pedersen, Birkerod, Denmark assigned to Novo Nordisk A/S In a method for effecting an increased expression in serum-free medium of recombinant proteins in a host cell being able to express said protein said host is cultured in a serum-free medium comprising an egg yolk fraction being free of fipoprotein and fipids so as to express said protein. Also the use of an egg yolk fraction being free of lipoprotein and fipids for increasing the expression of recombinant proteins in a host cell being able to express said